APRIL与宫颈癌的相关性研究
发布时间：2018-07-31 08:50
【摘要】：研究背景： APRIL(a proliferation-inducing ligand，增殖诱导配体)是肿瘤坏死因子(TNF)超家族的成员之一。有膜结合型、可溶型两种活性形式。二者均可以促进肿瘤细胞系的增殖。APRIL在正常组织中的表达量很低，但在肿瘤细胞株和肿瘤组织中如结直肠癌、肺癌、血液系统肿瘤、乳腺癌、黑色素瘤、膀胱癌等组织中均有高水平表达。早期临床研究发现，APRIL在宫颈鳞癌组织中的表达，无论在m RNA还是在蛋白水平均显著高于正常宫颈组织及鳞状上皮内病变组织，并且随着细胞增殖与异型性的加重，表达水平逐渐增高。但是，在目前尚无对于APRIL与宫颈癌的分期、分级、病理分型及淋巴结转移之间关联的报道，也未见有APRIL在癌组织中的表达与宫颈癌预后之间关联的报道。 本课题我们将研究APRIL与宫颈癌之间的关系，对正常宫颈组织或慢性宫颈炎组织、宫颈癌前病变组织、宫颈癌组织中的不同病理分型、分期、分级、淋巴结转移中APRIL蛋白表达情况进行研究，应用免疫组化法检测APRIL蛋白的表达情况，研究APRIL的表达与宫颈癌之间的关系，分析APRIL与宫颈癌的病理分型，分期，分级及淋巴结转移的关联。并应用生存分析方法回顾性分析行手术治疗的宫颈癌患者的临床病理资料，分析APRIL在宫颈癌组织中的表达与宫颈癌预后之间的关联，，同时对可能影响宫颈癌预后的多个因素进行单因素及多因素统计分析，用于指导术后辅助治疗。 临床研究发现，APRIL在宫颈鳞癌组织中的表达，随着细胞增殖与异型性的加重表达水平逐渐增高。根据以上研究结果，我们设想，APRIL蛋白的表达随宫颈癌的分型、分期、分级及淋巴结的转移增加而增加。为了验证以上设想，我们对77例宫颈癌患者病理切片中的APRIL蛋白进行检测，同时与30例正常或慢性宫颈炎组织及45例宫颈癌前病变组织进行比较，分析APRIL蛋白表达情况。再分析APRIL蛋白在癌组织中的表达与宫颈癌预后之间的关联。 第一部分各宫颈组织中APRIL蛋白的表达及其与宫颈癌的关系研究目的： 研究各宫颈组织中APRIL蛋白的表达及其与宫颈癌分型、分期、分级、淋巴结转移之间的关系。研究方法： 采用免疫组化法检测77例宫颈癌组织，30例正常或慢性宫颈炎组织及45例宫颈癌前病变组织中的APRIL蛋白表达水平。研究结果：1.正常或慢性宫颈炎组织，宫颈癌前病变组织，宫颈癌组织中APRIL蛋白表达比较，差异有统计学意义（p0.05）；2.不同分化的宫颈癌组织中的APRIL蛋白表达比较，差异有统计学意义（p0.05）；3.宫颈鳞癌，腺鳞癌，腺癌组织中APRIL蛋白表达比较，差异无统计学意义（p0.05）;4.不同分期的宫颈癌组织中APRIL蛋白表达比较，差异无统计学意义（p0.05）；5.宫颈癌患者有盆腔淋巴结转移者与无盆腔淋巴结转移者宫颈癌组织中的APRIL蛋白表达比较，差异无统计学意义（p0.05）。结论： APRIL蛋白在正常或慢性宫颈炎组织，宫颈癌前病变组织，宫颈癌组织中的表达呈递增趋势；APRIL蛋白的表达随宫颈癌的组织分化程度降低而增高，但其表达与宫颈癌的分期、临床病理分型及盆腔淋巴结转移无关。 第二部分宫颈癌组织中APRIL蛋白的表达与宫颈癌患者预后 的关联研究目的： 分析APRIL蛋白在癌组织中的表达与宫颈癌患者预后之间的关联，同时分析影响手术治疗宫颈癌患者预后的多个因素，用于指导术后辅助治疗。研究方法： 回顾性分析第一部分中行手术治疗的59例IB期及IIA期宫颈癌患者的临床病理资料，对7个非重复特征性因素进行单因素及多因素统计分析。研究结果： 59例患者5年生存率为81.4％，其中APRIL蛋白(-)为85.7％，APRIL蛋白（+）为80.8％；IB期为83.3％，IIA期为72.7％。APRIL蛋白(-)与APRIL蛋白（+）组的总体生存曲线差异无统计学意义(P0.05）。单因素生存分析得出与宫颈癌患者预后有关的因素有：临床病理分型、组织学分化、淋巴结转移(P0.05)。多因素生存分析显示临床病理分型、组织学分化及淋巴结转移是影响宫颈癌患者预后的危险因素(P0.05)。结论： 宫颈癌组织中APRIL蛋白的表达情况与预后无关；临床病理分型、组织分化程度以及淋巴结转移是影响早期宫颈癌患者预后的有关因素，早期宫颈癌患者可根据此影响预后因素指导术后辅助治疗。
[Abstract]:Research background:
APRIL (a proliferation-inducing ligand, proliferation inducing ligand) is one of the members of the tumor necrosis factor (TNF) superfamily. There are two forms of membrane binding and soluble type. The two can promote the proliferation of tumor cell lines with low expression in normal tissues, but in tumor cell lines and tumor tissues, such as colorectal cancer, lung Early clinical studies have found that the expression of APRIL in the squamous cell carcinoma of the cervix is significantly higher in M RNA or in protein levels than in normal cervical tissues and squamous epithelium, and with the increase of cell proliferation and heteromorphology, However, there are no reports of the association between the stages, classification, pathological classification and lymph node metastasis of APRIL and cervical cancer, and there are no reports of the association between the expression of APRIL in the cancer tissues and the prognosis of cervical cancer.
We will study the relationship between APRIL and cervical cancer, and study the expression of APRIL protein in the normal cervical tissue or chronic cervicitis, cervical precancerous tissue, cervical cancer tissues, different pathological types, stages, classification and lymph node metastasis. The expression of APRIL protein should be detected by immunohistochemical method, and APR should be studied. The relationship between the expression of IL and cervical cancer, the correlation between the pathological classification, staging, classification and lymph node metastasis of APRIL and cervical cancer, and a retrospective analysis of the clinicopathological data of the patients with cervical cancer treated by the survival analysis, and the correlation between the expression of APRIL in cervical cancer and the prognosis of cervical cancer. Univariate and multivariate statistical analyses were conducted on multiple factors that might affect the prognosis of cervical cancer, and were used to guide postoperative adjuvant therapy.
Clinical studies have found that the expression of APRIL in the squamous cell carcinoma of the cervix is increasing with the increasing expression of cell proliferation and heterotypic expression. According to the above findings, we envisage that the expression of APRIL protein increases with the classification, staging, classification and lymph node metastasis of cervical cancer. In order to verify the above assumption, we have 77 cases of cervix. The APRIL protein in the pathological sections of the cancer patients was detected and compared with 30 normal or chronic cervicitis and 45 cases of cervical precancerous lesions, and the expression of APRIL protein was analyzed. The relationship between the expression of APRIL protein in the cancer tissue and the prognosis of cervical cancer was analyzed.
Part one: the expression of APRIL protein in cervical tissues and its relationship with cervical cancer.
To study the expression of APRIL protein in cervical tissues and its relationship with the classification, staging, grading and lymph node metastasis of cervical cancer.
The expression of APRIL protein in 77 cases of cervical cancer, 30 cases of normal or chronic cervicitis and 45 cases of cervical precancerous lesions were detected by immunohistochemistry. Results: 1. normal or chronic cervicitis tissues, cervical precancerous lesions, and APRIL protein expression in cervical cancer tissues were statistically significant (P0.05); 2. There was significant difference in the expression of APRIL protein in the differentiated cervical cancer tissues (P0.05), and there was no significant difference in the expression of APRIL protein in 3. cervical squamous cell carcinoma, adenocarcinoma and adenocarcinoma tissue (P0.05), and there was no statistical difference between the APRIL protein table in 4. different stages of cervical cancer (P0.05); 5. cervical cancer patients. There was no significant difference in the expression of APRIL protein between patients with pelvic lymph node metastasis and those without pelvic lymph node metastasis (p0.05).
The expression of APRIL protein increased in normal or chronic cervicitis, precancerous tissue and cervical cancer tissue, and the expression of APRIL protein increased with the degree of tissue differentiation of cervical cancer, but its expression was not related to the stage of cervical cancer, clinicopathological classification and pelvic lymph node metastasis.
The second part is the expression of APRIL protein in cervical cancer and the prognosis of cervical cancer patients.
The purpose of the association study:
To analyze the association between the expression of APRIL protein in the cancer tissue and the prognosis of cervical cancer patients, and to analyze the factors affecting the prognosis of the patients with cervical cancer and to guide postoperative adjuvant therapy.
A retrospective analysis of the clinicopathological data of 59 patients with stage IB and IIA cervical cancer in the first part of the first part of the operation. A single factor and multiple factor analysis were performed on 7 non repetitive characteristic factors. The results were as follows:
The 5 year survival rate of 59 patients was 81.4%, of which APRIL protein (-) was 85.7%, APRIL protein (+) was 80.8%, IB phase was 83.3%, and the overall survival curve of 72.7%.APRIL protein (-) and APRIL protein (+) group was not statistically significant (P0.05). The factors associated with the prognosis of cervical cancer patients with single factor survival analysis were clinical pathology. Classification, histological differentiation, lymph node metastasis (P0.05). Multivariate survival analysis showed that the clinicopathological classification, histological differentiation and lymph node metastasis were risk factors for the prognosis of cervical cancer patients (P0.05).
The expression of APRIL protein in cervical cancer is not related to the prognosis. Clinicopathological classification, degree of tissue differentiation and lymph node metastasis are related factors affecting the prognosis of early cervical cancer patients. Early cervical cancer patients can guide postoperative adjuvant therapy according to the influence of prognostic factors.
【学位授予单位】：广西医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.33
本文编号：2155063
[Abstract]:Research background:
APRIL (a proliferation-inducing ligand, proliferation inducing ligand) is one of the members of the tumor necrosis factor (TNF) superfamily. There are two forms of membrane binding and soluble type. The two can promote the proliferation of tumor cell lines with low expression in normal tissues, but in tumor cell lines and tumor tissues, such as colorectal cancer, lung Early clinical studies have found that the expression of APRIL in the squamous cell carcinoma of the cervix is significantly higher in M RNA or in protein levels than in normal cervical tissues and squamous epithelium, and with the increase of cell proliferation and heteromorphology, However, there are no reports of the association between the stages, classification, pathological classification and lymph node metastasis of APRIL and cervical cancer, and there are no reports of the association between the expression of APRIL in the cancer tissues and the prognosis of cervical cancer.
We will study the relationship between APRIL and cervical cancer, and study the expression of APRIL protein in the normal cervical tissue or chronic cervicitis, cervical precancerous tissue, cervical cancer tissues, different pathological types, stages, classification and lymph node metastasis. The expression of APRIL protein should be detected by immunohistochemical method, and APR should be studied. The relationship between the expression of IL and cervical cancer, the correlation between the pathological classification, staging, classification and lymph node metastasis of APRIL and cervical cancer, and a retrospective analysis of the clinicopathological data of the patients with cervical cancer treated by the survival analysis, and the correlation between the expression of APRIL in cervical cancer and the prognosis of cervical cancer. Univariate and multivariate statistical analyses were conducted on multiple factors that might affect the prognosis of cervical cancer, and were used to guide postoperative adjuvant therapy.
Clinical studies have found that the expression of APRIL in the squamous cell carcinoma of the cervix is increasing with the increasing expression of cell proliferation and heterotypic expression. According to the above findings, we envisage that the expression of APRIL protein increases with the classification, staging, classification and lymph node metastasis of cervical cancer. In order to verify the above assumption, we have 77 cases of cervix. The APRIL protein in the pathological sections of the cancer patients was detected and compared with 30 normal or chronic cervicitis and 45 cases of cervical precancerous lesions, and the expression of APRIL protein was analyzed. The relationship between the expression of APRIL protein in the cancer tissue and the prognosis of cervical cancer was analyzed.
Part one: the expression of APRIL protein in cervical tissues and its relationship with cervical cancer.
To study the expression of APRIL protein in cervical tissues and its relationship with the classification, staging, grading and lymph node metastasis of cervical cancer.
The expression of APRIL protein in 77 cases of cervical cancer, 30 cases of normal or chronic cervicitis and 45 cases of cervical precancerous lesions were detected by immunohistochemistry. Results: 1. normal or chronic cervicitis tissues, cervical precancerous lesions, and APRIL protein expression in cervical cancer tissues were statistically significant (P0.05); 2. There was significant difference in the expression of APRIL protein in the differentiated cervical cancer tissues (P0.05), and there was no significant difference in the expression of APRIL protein in 3. cervical squamous cell carcinoma, adenocarcinoma and adenocarcinoma tissue (P0.05), and there was no statistical difference between the APRIL protein table in 4. different stages of cervical cancer (P0.05); 5. cervical cancer patients. There was no significant difference in the expression of APRIL protein between patients with pelvic lymph node metastasis and those without pelvic lymph node metastasis (p0.05).
The expression of APRIL protein increased in normal or chronic cervicitis, precancerous tissue and cervical cancer tissue, and the expression of APRIL protein increased with the degree of tissue differentiation of cervical cancer, but its expression was not related to the stage of cervical cancer, clinicopathological classification and pelvic lymph node metastasis.
The second part is the expression of APRIL protein in cervical cancer and the prognosis of cervical cancer patients.
The purpose of the association study:
To analyze the association between the expression of APRIL protein in the cancer tissue and the prognosis of cervical cancer patients, and to analyze the factors affecting the prognosis of the patients with cervical cancer and to guide postoperative adjuvant therapy.
A retrospective analysis of the clinicopathological data of 59 patients with stage IB and IIA cervical cancer in the first part of the first part of the operation. A single factor and multiple factor analysis were performed on 7 non repetitive characteristic factors. The results were as follows:
The 5 year survival rate of 59 patients was 81.4%, of which APRIL protein (-) was 85.7%, APRIL protein (+) was 80.8%, IB phase was 83.3%, and the overall survival curve of 72.7%.APRIL protein (-) and APRIL protein (+) group was not statistically significant (P0.05). The factors associated with the prognosis of cervical cancer patients with single factor survival analysis were clinical pathology. Classification, histological differentiation, lymph node metastasis (P0.05). Multivariate survival analysis showed that the clinicopathological classification, histological differentiation and lymph node metastasis were risk factors for the prognosis of cervical cancer patients (P0.05).
The expression of APRIL protein in cervical cancer is not related to the prognosis. Clinicopathological classification, degree of tissue differentiation and lymph node metastasis are related factors affecting the prognosis of early cervical cancer patients. Early cervical cancer patients can guide postoperative adjuvant therapy according to the influence of prognostic factors.
【学位授予单位】：广西医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.33
【参考文献】
相关期刊论文 前10条
1 王峰;陈琳;邵建国;毛振彪;;慢病毒载体介导RNA干扰体外抑制人胰腺癌细胞增殖诱导配体的表达[J];第二军医大学学报;2008年01期
2 胡海霞;曹治云;刘志臻;陈旭征;杜建;;扶正抑瘤方对肝癌组织中增殖诱导配体及其受体表达的影响[J];福建中医药大学学报;2011年01期
3 关婧;孙爱民;王莉慧;何美蓉;;慢病毒介导RNAi抑制大肠癌细胞APRIL表达对化疗敏感性的影响[J];南方医科大学学报;2011年09期
4 刘宝英;郑英如;何凤田;李蓉芬;龚薇;黄刚;;人可溶性TALL-2突变体的原核表达及纯化[J];第三军医大学学报;2006年23期
5 于杰;龚治林;;增殖诱导配体和受体在大肠癌中的表达及其临床意义[J];长江大学学报(自然科学版)医学卷;2010年03期
6 罗泽宇;申建凯;张广森;;B细胞活化因子/增殖诱导配体在多发性骨髓瘤中的表达特点和临床意义[J];临床血液学杂志;2009年02期
7 张桂华;陆德炎;陈令松;张秋荣;徐金格;陈宁;;增殖诱导配体检测在B细胞非霍奇金淋巴瘤中的临床意义[J];临床血液学杂志;2012年05期
8 郭云蔚;文卓夫;尉秀清;郑丰平;;原发性肝癌APRIL表达与临床病理生理特点[J];中国热带医学;2009年01期
9 戴双双,何凤田,张艳,李蓉芬,杨朝辉,彭家和;人可溶性APRIL(sAPRIL)基因的克隆及在大肠杆菌中的表达[J];生物工程学报;2004年06期
10 施健;张冬雷;崔之础;毛振彪;邱亚萍;唐卫东;;增殖诱导配体及其受体在肿瘤组织中的表达与意义[J];检验医学;2007年02期
相关博士学位论文 前1条
1 郑英如;APRIL及其受体在宫颈癌细胞中的表达以及APRIL突变体的制备[D];第三军医大学;2007年
本文编号：2155063
本文链接：https://www.wllwen.com/yixuelunwen/fuchankeerkelunwen/2155063.html
最近更新
教材专著
